Summary

Liquid Biopsy Market By Product Type (Assays and Kits, Instruments, and Services), By Application (Early Cancer Detection, Recurrence Monitoring, Prenatal Testing, Organ Transplant Monitoring, and Others), By Biomarker Type (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Microvesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, and Others), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Prenatal Testing, and Others), and By End-User (Hospitals and Clinics, Diagnostic Laboratories, Pharma & Biotech Companies, and Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 ? 2035
The Liquid Biopsy market accounted for USD 8.4 billion in 2024 and is expected to reach USD 33.82 billion by 2035, growing at a CAGR of around 13.5% between 2025 and 2035. The non-invasive diagnostic procedure of liquid biopsy revolves around the recognition of biomarkers in blood and other body fluids to find cancers, including ctDNA, CTCs, and exosomes. It offers a much safer and faster alternative to tissue biopsy. The technique is catching on for early cancer detection, monitoring treatment, and tracking recurrences. Genomic technologies are reportedly being improved, leading to a surge in personalized medicine needs and awareness that grows from understanding diagnostics early in cancer. Research is progressively shifting beyond oncology to include prenatal testing and transplant monitoring. The fact that regulation is getting better and that there is better public investment in precision health indicates that rapid market evolution is expected. Corporations are concentrating their effort on developing more accurate, cost-effective solutions that would tend towards scalability in a manner appropriate to global healthcare needs. The adoption will eventually take off across clinical and research settings by liquid biopsy, which overall means that the market is in continued growth.
Emphasis on Non-Invasive Diagnostics
A close focus of the medical community is on their preference for non-invasive diagnostics, and the liquid biopsy tests complement their view. It studies circulating biomarkers in body fluids rather than having to resort to tissue biopsy, thus giving a less invasive approach. Apart from this, it has less discomfort and fewer risks attached to the surgical open and invasive methods. Further, it permits closer monitoring of the progression of disease and response to treatment. Even further, the performance and safety of the liquid biopsy have continued to be favored, driving its clinical application. As much as healthcare systems are focusing more on patient-centeredness, so is an increase in demand for such minimally invasive procedures.
Variation of Test Sensitivity and Specificity
Although advances have been made, liquid biopsy tests may vary in the performance of sensitivity and specificity for different cancer types and stages. While some tumors do not shed enough biomarkers into the bloodstream, leading to false negatives, false positives, on the other end, are encountered through benign conditions, resulting in undue anxiety and intervention. The inconsistent data make it difficult for clinical decision-making, restricting the adoption of liquid biopsy into routine medical practice. Achieving consistency and accuracy across patient populations remains a significant challenge for the industry.
Integration with Personalized Medicine
The rise of personalized medicine offers new avenues for liquid biopsy testing. Tumor genetics can be determined in real-time through liquid biopsy, aiding in the development of personalized treatment programs based on an individual patient's profile. Efficacy is thus enhanced while limiting untoward effects. Besides, the liquid biopsy determines treatment response and can also help identify resistance mutations that trigger a change in therapy. The partnership of liquid biopsy with personalized medicine will vastly transform cancer management with immense market possibilities.
Segment Analysis
Technologies in this segmentation are PCR, NGS, and microarray technologies. PCR techniques are most commonly used because of their sensitivity and cost-effectiveness in the detection of known genetic mutations. Nuclear magnetic resonance provides high-throughput analysis to identify a wide variety of genetic alterations, thus being suitable for broadly based genomic profiling. Microarrays allow the simultaneous analysis of several biomarkers to provide vital data for both research and diagnostic purposes. The specific option taken by any lab will depend on factors such as required depth of analysis, turnaround time, or cost considerations, which translate to different market adoption patterns in various clinical environments.
Applications of liquid biopsies include early cancer detection, recurrence monitoring, and prenatal testing, among others. Applications for early detection focus on identifying cancers in asymptomatic stages so that treatment becomes more effective. Recurrence monitoring seeks to maintain residual disease status and detect relapses, permitting timely interventions. Liquid biopsy may be used in prenatal testing to assess fetal genetic conditions non-invasively, thus mitigating the risks of conventional methods. This flexibility in applications for both oncology and non-oncology practice renders liquid biopsy technologies precious commodities in the advancement of both fields and thus spurs market growth.

Regional Analysis
The North American market for liquid biopsies is highly lucrative, with advanced healthcare infrastructure and emphasis on research and development being the two most significant drivers. The presence of leading biotechnology firms and academic institutions promotes innovation and the rapid uptake of new diagnostic tools. Meanwhile, an adaptation of regulations within the region allows for market entry for newer technologies. Also, growing awareness among healthcare professionals and patients about the benefits of liquid biopsies supports their clinical application. The focus on personalized medicine further drives demand for these tests, ensuring North America's footprint in the global market.
Competitive Landscape
High competition, characterized by rivalries among established players and upcoming startups, marks the entry into the liquid biopsy market. Industry leaders include Guardant Health, Illumina, Thermo Fisher Scientific, and QIAGEN, with established product portfolios and intense research pursuits. They are investing in launching new advanced assays and further expanding the reach of these tests through acquisition and partnership strategies. New entrants are developing competitive advantages in niche applications and technologies. The fast-changing nature of this market, coupled with rapid advancements in technology, calls for continuous innovation and flexibility. Thus, the key to success in this market is to provide highly accurate, cost-effective, and clinically endorsed solutions that satisfy the emerging needs of patients and healthcare professionals.
Report Coverage:
By Product Type
- Assays and Kits
- Instruments
- Services
By Application
- Early Cancer Detection
- Recurrence Monitoring
- Prenatal Testing
- Organ Transplant Monitoring
- Others
By Biomarker Type
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Microvesicles
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Microarray
- Others
By Indication
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Pancreatic Cancer
- Prenatal testing
- Others
By End-User
- Hospitals and Clinics
- Diagnostic Laboratories
- Pharma & Biotech Companies
- Research Institutes

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Global Liquid Biopsy Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Rising cancer cases boost liquid biopsy adoption for diagnostics.
3.2.2. Minimally invasive approach increases patient preference over tissue biopsies.
3.2.3. Precision medicine demands personalized, non-invasive liquid biopsy techniques.
3.3. Key industry pitfalls & challenges
3.3.1. Sensitivity challenges hinder detection of low-frequency cancer mutations.
3.3.2. Strict regulatory requirements slow the approval of new technologies.
3.3.3. High test costs limit liquid biopsy access in developing regions.
3.4. Market Opportunities
3.4.1. AI integration improves data accuracy and automated liquid biopsy diagnostics.
3.4.2. Emerging markets present growth potential with expanding healthcare infrastructure.
3.4.3. Multi-cancer detection creates opportunities for comprehensive early screening.
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Pipeline Analysis
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. Liquid Biopsy Market, Product Type Segment Analysis
4.1. Overview Dynamics
4.1.1. Market Revenue Share, By Product Type, 2025 & 2035
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Assays and Kits
4.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
4.3. Instruments
4.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
4.4. Services
4.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
5. Liquid Biopsy Market, Application Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Application, 2025 & 2035
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Early Cancer Detection
5.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.3. Recurrence Monitoring
5.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.4. Prenatal Testing
5.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.5. Organ Transplant Monitoring
5.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
5.6. Others
5.6.1. Market Size and Forecast, By 2025-2035(USD Billion)
6. Liquid Biopsy Market, Biomarker Type Segment Analysis
6.1. Overview
6.1.1. Market Revenue Share, By Biomarker Type, 2025 & 2035
6.1.2. Key Market Trends, Growth Factors, & Opportunities
6.2. Circulating Tumor Cells (CTCs)
6.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.3. Circulating Tumor DNA (ctDNA)
6.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.4. Microvesicles
6.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
6.5. Others
6.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
7. Liquid Biopsy Market, Technology Segment Analysis
7.1. Overview
7.1.1. Market Revenue Share, By Technology, 2025 & 2035
7.1.2. Key Market Trends, Growth Factors, & Opportunities
7.2. Polymerase Chain Reaction (PCR)
7.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.3. Next-Generation Sequencing (NGS)
7.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.4. Microarray
7.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
7.5. Others
7.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
8. Liquid Biopsy Market, Indication Segment Analysis
8.1. Overview
8.1.1. Market Revenue Share, By Indication, 2025 & 2035
8.1.2. Key Market Trends, Growth Factors, & Opportunities
8.2. Lung Cancer
8.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.3. Breast Cancer
8.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.4. Colorectal Cancer
8.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.5. Prostate Cancer
8.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.6. Pancreatic Cancer
8.6.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.7. Prenatal testing
8.7.1. Market Size and Forecast, By 2025-2035(USD Billion)
8.8. Others
8.8.1. Market Size and Forecast, By 2025-2035(USD Billion)
9. Liquid Biopsy Market, End-User Segment Analysis
9.1. Overview
9.1.1. Market Revenue Share, By End-User, 2025 & 2035
9.1.2. Key Market Trends, Growth Factors, & Opportunities
9.2. Hospitals and Clinics
9.2.1. Market Size and Forecast, By 2025-2035(USD Billion)
9.3. Diagnostic Laboratories
9.3.1. Market Size and Forecast, By 2025-2035(USD Billion)
9.4. Pharma & Biotech Companies
9.4.1. Market Size and Forecast, By 2025-2035(USD Billion)
9.5. Research Institutes
9.5.1. Market Size and Forecast, By 2025-2035(USD Billion)
10. Liquid Biopsy Market, Region Segment Analysis
10.1. Overview
10.1.1. Global Market Revenue Share, By Region, 2025 & 2035
10.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)
10.2. North America
10.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)
10.2.2. North America Market Revenue, By Product Type, 2025-2035
10.2.3. North America Market Revenue, By Application, 2025-2035
10.2.4. North America Market Revenue, By Biomarker Type, 2025-2035
10.2.5. North America Market Revenue, By Technology, 2025-2035
10.2.6. North America Market Revenue, By Indication, 2025-2035
10.2.7. North America Market Revenue, By End-User, 2025-2035
10.2.8. The U.S.
10.2.8.1. U.S. Market Revenue, By Product Type, 2025-2035
10.2.8.2. U.S. Market Revenue, By Application, 2025-2035
10.2.8.3. U.S. Market Revenue, By Biomarker Type, 2025-2035
10.2.8.4. U.S. Market Revenue, By Technology, 2025-2035
10.2.8.5. U.S. Market Revenue, By Indication, 2025-2035
10.2.8.6. U.S. Market Revenue, By End-User, 2025-2035
10.2.9. Canada
10.2.9.1. Canada Market Revenue, By Product Type, 2025-2035
10.2.9.2. Canada Market Revenue, By Application, 2025-2035
10.2.9.3. Canada Market Revenue, By Biomarker Type, 2025-2035
10.2.9.4. Canada Market Revenue, By Technology, 2025-2035
10.2.9.5. Canada Market Revenue, By Indication, 2025-2035
10.2.9.6. Canada Market Revenue, By End-User, 2025-2035
10.3. Europe
10.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)
10.3.2. Europe Market Revenue, By Product Type, 2025-2035
10.3.3. Europe Market Revenue, By Application, 2025-2035
10.3.4. Europe Market Revenue, By Biomarker Type, 2025-2035
10.3.5. Europe Market Revenue, By Technology, 2025-2035
10.3.6. Europe Market Revenue, By Indication, 2025-2035
10.3.7. Europe Market Revenue, By End-User, 2025-2035
10.3.8. Germany
10.3.8.1. Germany Market Revenue, By Product Type, 2025-2035
10.3.8.2. Germany Market Revenue, By Application, 2025-2035
10.3.8.3. Germany Market Revenue, By Biomarker Type, 2025-2035
10.3.8.4. Germany Market Revenue, By Technology, 2025-2035
10.3.8.5. Germany Market Revenue, By Indication, 2025-2035
10.3.8.6. Germany Market Revenue, By End-User, 2025-2035
10.3.9. France
10.3.9.1. France Market Revenue, By Product Type, 2025-2035
10.3.9.2. France Market Revenue, By Application, 2025-2035
10.3.9.3. France Market Revenue, By Biomarker Type, 2025-2035
10.3.9.4. France Market Revenue, By Technology, 2025-2035
10.3.9.5. France Market Revenue, By Indication, 2025-2035
10.3.9.6. France Market Revenue, By End-User, 2025-2035
10.3.10. U.K.
10.3.10.1. U.K. Market Revenue, By Product Type, 2025-2035
10.3.10.2. U.K. Market Revenue, By Application, 2025-2035
10.3.10.3. U.K Market Revenue, By Biomarker Type, 2025-2035
10.3.10.4. U.K Market Revenue, By Technology, 2025-2035
10.3.10.5. U.K Market Revenue, By Indication, 2025-2035
10.3.10.6. U.K. Market Revenue, By End-User, 2025-2035
10.3.11. Italy
10.3.11.1. Italy Market Revenue, By Product Type, 2025-2035
10.3.11.2. Italy Market Revenue, By Application, 2025-2035
10.3.11.3. Italy Market Revenue, By Biomarker Type, 2025-2035
10.3.11.4. Italy Market Revenue, By Technology, 2025-2035
10.3.11.5. Italy Market Revenue, By Indication, 2025-2035
10.3.11.6. Italy Market Revenue, By End-User, 2025-2035
10.3.12. Spain
10.3.12.1. Spain Market Revenue, By Product Type, 2025-2035
10.3.12.2. Spain Market Revenue, By Application, 2025-2035
10.3.12.3. Spain Market Revenue, By Biomarker Type, 2025-2035
10.3.12.4. Spain Market Revenue, By Technology, 2025-2035
10.3.12.5. Spain Market Revenue, By Indication, 2025-2035
10.3.12.6. Spain Market Revenue, By End-User, 2025-2035
10.3.13. Rest of Europe
10.3.13.1. Germany Market Revenue, By Product Type, 2025-2035
10.3.13.2. Germany Market Revenue, By Application, 2025-2035
10.3.13.3. Germany Market Revenue, By Biomarker Type, 2025-2035
10.3.13.4. Germany Market Revenue, By Technology, 2025-2035
10.3.13.5. Germany Market Revenue, By Indication, 2025-2035
10.3.13.6. Germany Market Revenue, By End-User, 2025-2035
10.4. Asia Pacific
10.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)
10.4.2. Asia Pacific Market Revenue, By Product Type, 2025-2035
10.4.3. Asia Pacific Market Revenue, By Application, 2025-2035
10.4.4. Asia Pacific Market Revenue, By Biomarker Type, 2025-2035
10.4.5. Asia Pacific Market Revenue, By Technology, 2025-2035
10.4.6. Asia Pacific Market Revenue, By Indication, 2025-2035
10.4.7. Asia Pacific Market Revenue, By End-User, 2025-2035
10.4.8. China
10.4.8.1. China Market Revenue, By Product Type, 2025-2035
10.4.8.2. China Market Revenue, By Application, 2025-2035
10.4.8.3. China Market Revenue, By Biomarker Type, 2025-2035
10.4.8.4. China Market Revenue, By Technology, 2025-2035
10.4.8.5. China Market Revenue, By Indication, 2025-2035
10.4.8.6. China Market Revenue, By End-User, 2025-2035
10.4.9. Japan
10.4.9.1. Japan Market Revenue, By Product Type, 2025-2035
10.4.9.2. Japan Market Revenue, By Application, 2025-2035
10.4.9.3. Japan Market Revenue, By Biomarker Type, 2025-2035
10.4.9.4. Japan Market Revenue, By Technology, 2025-2035
10.4.9.5. Japan Market Revenue, By Indication, 2025-2035
10.4.9.6. Japan Market Revenue, By End-User, 2025-2035
10.4.10. India
10.4.10.1. India Market Revenue, By Product Type, 2025-2035
10.4.10.2. India Market Revenue, By Application, 2025-2035
10.4.10.3. India Market Revenue, By Biomarker Type, 2025-2035
10.4.10.4. India Market Revenue, By Technology, 2025-2035
10.4.10.5. India Market Revenue, By Indication, 2025-2035
10.4.10.6. India Market Revenue, By End-User, 2025-2035
10.4.11. Australia
10.4.11.1. Australia Market Revenue, By Product Type, 2025-2035
10.4.11.2. Australia Market Revenue, By Application, 2025-2035
10.4.11.3. Australia Market Revenue, By Biomarker Type, 2025-2035
10.4.11.4. Australia Market Revenue, By Technology, 2025-2035
10.4.11.5. Australia Market Revenue, By Indication, 2025-2035
10.4.11.6. Australia Market Revenue, By End-User, 2025-2035
10.4.12. South Korea
10.4.12.1. South Korea Market Revenue, By Product Type, 2025-2035
10.4.12.2. South Korea Market Revenue, By Application, 2025-2035
10.4.12.3. South Korea Market Revenue, By Biomarker Type, 2025-2035
10.4.12.4. South Korea Market Revenue, By Technology, 2025-2035
10.4.12.5. South Korea Market Revenue, By Indication, 2025-2035
10.4.12.6. South Korea Market Revenue, By End-User, 2025-2035
10.4.13. Singapore
10.4.13.1. Singapore Market Revenue, By Product Type, 2025-2035
10.4.13.2. Singapore Market Revenue, By Application, 2025-2035
10.4.13.3. Singapore Canada Market Revenue, By Biomarker Type, 2025-2035
10.4.13.4. Singapore Market Revenue, By Technology, 2025-2035
10.4.13.5. Singapore Market Revenue, By Indication, 2025-2035
10.4.13.6. Singapore Market Revenue, By End-User, 2025-2035
10.4.14. Rest of Asia Pacific
10.4.14.1. Rest of Asia Pacific Market Revenue, By Product Type, 2025-2035
10.4.14.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035
10.4.14.3. Rest of Asia Pacific Market Revenue, By Biomarker Type, 2025-2035
10.4.14.4. Rest of Asia Pacific Market Revenue, By Technology, 2025-2035
10.4.14.5. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035
10.4.14.6. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035
10.5. Latin America
10.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)
10.5.2. Latin America Market Revenue, By Product Type, 2025-2035
10.5.3. Latin America Market Revenue, By Application, 2025-2035
10.5.4. Latin America Market Revenue, By Biomarker Type, 2025-2035
10.5.5. Latin America Market Revenue, By Technology, 2025-2035
10.5.6. Latin America Market Revenue, By Indication, 2025-2035
10.5.7. Latin America Market Revenue, By End-User, 2025-2035
10.5.7.1. Brazil Market Revenue, By Product Type, 2025-2035
10.5.7.2. Brazil Market Revenue, By Application, 2025-2035
10.5.7.3. Brazil Market Revenue, By Biomarker Type, 2025-2035
10.5.7.4. Brazil Market Revenue, By Technology, 2025-2035
10.5.7.5. Brazil Market Revenue, By Indication, 2025-2035
10.5.7.6. Brazil Market Revenue, By End-User, 2025-2035
10.5.8. Argentina
10.5.8.1. Argentina Market Revenue, By Product Type, 2025-2035
10.5.8.2. Argentina Market Revenue, By Application, 2025-2035
10.5.8.3. Argentina Market Revenue, By Biomarker Type, 2025-2035
10.5.8.4. Argentina Market Revenue, By Technology, 2025-2035
10.5.8.5. Argentina Market Revenue, By Indication, 2025-2035
10.5.8.6. Argentina Market Revenue, By End-User, 2025-2035
10.5.9. Mexico
10.5.9.1. Mexico Market Revenue, By Product Type, 2025-2035
10.5.9.2. Mexico Market Revenue, By Application, 2025-2035
10.5.9.3. Mexico Market Revenue, By Biomarker Type, 2025-2035
10.5.9.4. Mexico Market Revenue, By Technology, 2025-2035
10.5.9.5. Mexico Market Revenue, By Indication, 2025-2035
10.5.9.6. Mexico Market Revenue, By End-User, 2025-2035
10.5.10. Rest of Latin America
10.5.10.1. Rest of Latin America Market Revenue, By Product Type, 2025-2035
10.5.10.2. Rest of Latin America Market Revenue, By Application, 2025-2035
10.5.10.3. Rest of Latin America Market Revenue, By Biomarker Type, 2025-2035
10.5.10.4. Rest of Latin America Market Revenue, By Technology, 2025-2035
10.5.10.5. Rest of Latin America Market Revenue, By Indication, 2025-2035
10.5.10.6. Rest of Latin America Market Revenue, By End-User, 2025-2035
10.6. MEA
10.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)
10.6.2. MEA Market Revenue, By Product Type, 2025-2035
10.6.3. MEA Market Revenue, By Application, 2025-2035
10.6.4. MEA Market Revenue, By Biomarker Type, 2025-2035
10.6.5. MEA Market Revenue, By Technology, 2025-2035
10.6.6. MEA Market Revenue, By Indication, 2025-2035
10.6.7. MEA Market Revenue, By End-User, 2025-2035
10.6.8. GCC Countries
10.6.8.1. GCC Countries Market Revenue, By Product Type, 2025-2035
10.6.8.2. GCC Countries Market Revenue, By Application, 2025-2035
10.6.8.3. GCC Countries Market Revenue, By Biomarker Type, 2025-2035
10.6.8.4. GCC Countries Market Revenue, By Technology, 2025-2035
10.6.8.5. GCC Countries Market Revenue, By Indication, 2025-2035
10.6.8.6. GCC Countries Market Revenue, By End-User, 2025-2035
10.6.9. South Africa
10.6.9.1. South Africa Countries Market Revenue, By Product Type, 2025-2035
10.6.9.2. South Africa Countries Market Revenue, By Application, 2025-2035
10.6.9.3. South Africa Countries Market Revenue, By Biomarker Type, 2025-2035
10.6.9.4. South Africa Countries Market Revenue, By Technology, 2025-2035
10.6.9.5. South Africa Countries Market Revenue, By Indication, 2025-2035
10.6.9.6. South Africa Countries Market Revenue, By End-User, 2025-2035
10.6.10. Rest of Middle-East Africa
10.6.10.1. Rest of Middle-East Africa Countries Market Revenue, By Product Type, 2025-2035
10.6.10.2. Rest of Middle-East Africa Countries Market Revenue, By Application, 2025-2035
10.6.10.3. Rest of Middle-East Africa Countries Market Revenue, By Biomarker Type, 2025-2035
10.6.10.4. Rest of Middle-East Africa Countries Market Revenue, By Technology, 2025-2035
10.6.10.5. Rest of Middle-East Africa Countries Market Revenue, By Indication, 2025-2035
10.6.10.6. Rest of Middle-East Africa Countries Market Revenue, By End-User, 2025-2035
11. Company Profile
11.1. Guardant Health, Inc.
11.1.1. Business Overview
11.1.2. Financial Performance
11.1.3. Product/Service Offerings
11.1.4. Strategies & recent developments
11.1.5. SWOT Analysis
11.2. Biocept, Inc.
11.2.1. Business Overview
11.2.2. Financial Performance
11.2.3. Product/Service Offerings
11.2.4. Strategies & recent developments
11.2.5. SWOT Analysis
11.3. Qiagen N.V.
11.3.1. Business Overview
11.3.2. Financial Performance
11.3.3. Product/Service Offerings
11.3.4. Strategies & recent developments
11.3.5. SWOT Analysis
11.4. F. Hoffmann-La Roche Ltd.
11.4.1. Business Overview
11.4.2. Financial Performance
11.4.3. Product/Service Offerings
11.4.4. Strategies & recent developments
11.4.5. SWOT Analysis
11.5. Thermo Fisher Scientific Inc.
11.5.1. Business Overview
11.5.2. Financial Performance
11.5.3. Product/Service Offerings
11.5.4. Strategies & recent developments
11.5.5. SWOT Analysis
11.6. Illumina, Inc.
11.6.1. Business Overview
11.6.2. Financial Performance
11.6.3. Product/Service Offerings
11.6.4. Strategies & recent developments
11.6.5. SWOT Analysis
11.7. Adaptive Biotechnologies Corporation
11.7.1. Business Overview
11.7.2. Financial Performance
11.7.3. Product/Service Offerings
11.7.4. Strategies & recent developments
11.7.5. SWOT Analysis
11.8. Exact Sciences Corporation
11.8.1. Business Overview
11.8.2. Financial Performance
11.8.3. Product/Service Offerings
11.8.4. Strategies & recent developments
11.8.5. SWOT Analysis
11.9. Freenome Holdings, Inc.
11.9.1. Business Overview
11.9.2. Financial Performance
11.9.3. Product/Service Offerings
11.9.4. Strategies & recent developments
11.9.5. SWOT Analysis
11.10. Natera, Inc.
11.10.1. Business Overview
11.10.2. Financial Performance
11.10.3. Product/Service Offerings
11.10.4. Strategies & recent developments
11.10.5. SWOT Analysis
11.11. Personal Genome Diagnostics, Inc.
11.11.1. Business Overview
11.11.2. Financial Performance
11.11.3. Product/Service Offerings
11.11.4. Strategies & recent developments
11.11.5. SWOT Analysis
11.12. MDxHealth SA
11.12.1. Business Overview
11.12.2. Financial Performance
11.12.3. Product/Service Offerings
11.12.4. Strategies & recent developments
11.12.5. SWOT Analysis
11.13. Grail, Inc.
11.13.1. Business Overview
11.13.2. Financial Performance
11.13.3. Product/Service Offerings
11.13.4. Strategies & recent developments
11.13.5. SWOT Analysis
11.14. Foundation Medicine, Inc.
11.14.1. Business Overview
11.14.2. Financial Performance
11.14.3. Product/Service Offerings
11.14.4. Strategies & recent developments
11.14.5. SWOT Analysis
11.15. Inivata Limited
11.15.1. Business Overview
11.15.2. Financial Performance
11.15.3. Product/Service Offerings
11.15.4. Strategies & recent developments
11.15.5. SWOT Analysis

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. GLOBAL LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 2. GLOBAL LIQUID BIOPSY MARKET VALUE FOR ACTIVATED CARBON, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 3. GLOBAL LIQUID BIOPSY MARKET VALUE FOR CARBON DERIVATIVES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 4. GLOBAL LIQUID BIOPSY MARKET VALUE FOR METAL OXIDES, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 5. GLOBAL LIQUID BIOPSY MARKET VALUE FOR CONDUCTIVE POLYMERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 6. GLOBAL LIQUID BIOPSY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 7. GLOBAL LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 8. GLOBAL LIQUID BIOPSY MARKET VALUE FOR CONSUMER ELECTRONICS, 2025-2035 (USD BILLION)
TABLE 9. GLOBAL LIQUID BIOPSY MARKET VALUE FOR INDUSTRIAL, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 10. GLOBAL LIQUID BIOPSY MARKET VALUE FOR TRANSPORTATION, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 11. GLOBAL LIQUID BIOPSY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2025-2035 (USD BILLION)
TABLE 12. NORTH AMERICA LIQUID BIOPSY MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 13. NORTH AMERICA LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 14. NORTH AMERICA LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 15. U.S LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 16. U.S LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 17. CANADA LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 18. CANADA LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 19. EUROPE LIQUID BIOPSY MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 20. EUROPE LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 21. EUROPE LIQUID BIOPSY MARKET VALUE, APPLICATION, 2025-2035 (USD BILLION)
TABLE 22. GERMANY LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 23. GERMANY LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 24. U.K LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 25. U.K LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 26. FRANCE LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 27. FRANCE LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 28. ITALY LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 29. ITALY LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 30. SPAIN LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 31. SPAIN LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 32. ROE LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 33. ROE LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 34. ASIA PACIFIC LIQUID BIOPSY MARKET VALUE, BY COUNTRY, 2025-2035 (USD BILLION)
TABLE 35. ASIA PACIFIC LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 36. ASIA PACIFIC LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 37. CHINA LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 38. CHINA LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 39. INDIA LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 40. INDIA LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 41. JAPAN LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 42. JAPAN LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 43. REST OF APAC LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 44. REST OF APAC LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 45. REST OF WORLD LIQUID BIOPSY MARKET VALUE, BY TECHNOLOGY, 2025-2035 (USD BILLION)
TABLE 46. REST OF WORLD LIQUID BIOPSY MARKET VALUE, BY APPLICATION, 2025-2035 (USD BILLION)
TABLE 47. CABOT(NORIT): FINANCIALS
TABLE 48. CABOT(NORIT): PRODUCTS & SERVICES
TABLE 49. CABOT(NORIT): RECENT DEVELOPMENTS
TABLE 50. KURARY CO. LTD: FINANCIALS
TABLE 51. KURARY CO. LTD: PRODUCTS & SERVICES
TABLE 52. KURARY CO. LTD: RECENT DEVELOPMENTS
TABLE 53. BAYER MATERIALSCIENCE AG: FINANCIALS
TABLE 54. BAYER MATERIALSCIENCE AG: PRODUCTS & SERVICES
TABLE 55. BAYER MATERIALSCIENCE AG: RECENT DEVELOPMENTS
TABLE 56. CALGON CARBON CORPORATION: FINANCIALS
TABLE 57. CALGON CARBON CORPORATION: PRODUCTS & SERVICES
TABLE 58. CALGON CARBON CORPORATION: RECENT DEVELOPMENTS
TABLE 59. CARBON NT&F: FINANCIALS
TABLE 60. CARBON NT&F: PRODUCTS & SERVICES
TABLE 61. CARBON NT&F: RECENT DEVELOPMENTS
TABLE 62. SHENZHEN NTP: FINANCIALS
TABLE 63. SHENZHEN NTP: PRODUCTS & SERVICES
TABLE 64. SHENZHEN NTP: RECENT DEVELOPMENTS
TABLE 65. CECA SA: FINANCIALS
TABLE 66. CECA SA: PRODUCTS & SERVICES
TABLE 67. CECA SA: RECENT DEVELOPMENTS
TABLE 68. CNANO TECHNOLOGY: FINANCIALS
TABLE 69. CNANO TECHNOLOGY: PRODUCTS & SERVICES
TABLE 70. CNANO TECHNOLOGY: RECENT DEVELOPMENTS
TABLE 71. DONAU CHEMIE GROUP: FINANCIALS
TABLE 72. DONAU CHEMIE GROUP: PRODUCTS & SERVICES
TABLE 73. DONAU CHEMIE GROUP: RECENT DEVELOPMENTS
TABLE 74. SHOWA DENKO: FINANCIALS
TABLE 75. SHOWA DENKO: PRODUCTS & SERVICES
TABLE 76. SHOWA DENKO: RECENT DEVELOPMENTS